Mesenchymal stem cell-based therapy for autoimmune-related fibrotic skin diseases-systemic sclerosis and sclerodermatous graft-versus-host disease.
Han YangSousan CheongYunfan HeFeng LuPublished in: Stem cell research & therapy (2023)
The application of MSCs presents a promising approach for treating autoimmune-related fibrotic skin diseases: SSc and Scl-GVHD. Therapies involving MSCs and MSC extracellular vesicles have been found to operate through three primary mechanisms: rebalancing the immune and inflammatory disorders, resisting oxidant stress, and inhibiting overactivated fibrosis (including fibroblast activation and ECM remodeling). However, the effectiveness of these interventions requires further validation through extensive clinical investigations, particularly randomized control trials and phase III/IV clinical trials. Additionally, the hypothetical mechanism underlying these therapies could be elucidated through further research.
Keyphrases
- systemic sclerosis
- phase iii
- clinical trial
- mesenchymal stem cells
- open label
- interstitial lung disease
- double blind
- phase ii
- placebo controlled
- umbilical cord
- multiple sclerosis
- wound healing
- soft tissue
- randomized controlled trial
- drug induced
- systematic review
- signaling pathway
- physical activity
- idiopathic pulmonary fibrosis
- rheumatoid arthritis
- allogeneic hematopoietic stem cell transplantation
- liver fibrosis